TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy

(2019) Imran Siddiqui et al.   IMMUNITY

TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma

(2019) Sarah E Josefsson et al.   Cancer Immunology Research

GITR ligation enhances functionality of tumor‐infiltrating T cells in hepatocellular carcinoma

(2019) Adriaan A. Beek et al.   INTERNATIONAL JOURNAL OF CANCER

TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma

(2019) Xiaochen Wang et al.   JOURNAL OF HEPATOLOGY

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection

(2019) Francesca Alfei et al.   NATURE

TOX is a critical regulator of tumour-specific T cell differentiation

(2019) Andrew C. Scott et al.   NATURE

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

(2019) Omar Khan et al.   NATURE

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma

(2019) Xiaoli Liu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision

(2019) Zeyu Chen et al.   IMMUNITY

PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma

(2019) Jiaqiang Ma et al.   Journal for ImmunoTherapy of Cancer

VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers

(2019) Chang Gon Kim et al.   Science Immunology

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity

(2018) Karen O. Dixon et al.   JOURNAL OF IMMUNOLOGY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

(2018) Thomas Duhen et al.   Nature Communications

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma

(2018) Hyung-Don Kim et al.   GASTROENTEROLOGY

Human CD96 correlates to NK cell exhaustion and predicts the prognosis of human hepatocellular carcinoma

(2018) Haoyu Sun et al.   HEPATOLOGY

Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas

(2017) Guoying Zhou et al.   GASTROENTEROLOGY

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma

(2017) Kostandinos Sideras et al.   OncoImmunology

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

(2016) Jennifer E. Kim et al.   CLINICAL CANCER RESEARCH

Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase

(2016) Takashi Inozume et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

(2016) Se Jin Im et al.   NATURE

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area

(2015) K Sideras et al.   BRITISH JOURNAL OF CANCER

Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells

(2015) Gerharda H. Boerman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

(2015) Joe-Marc Chauvin et al.   JOURNAL OF CLINICAL INVESTIGATION

TIGIT predominantly regulates the immune response via regulatory T cells

(2015) Sema Kurtulus et al.   JOURNAL OF CLINICAL INVESTIGATION

Increased CD226 Expression on CD8+T Cells Is Associated with Upregulated Cytokine Production and Endothelial Cell Injury in Patients with Systemic Sclerosis

(2015) Masahiro Ayano et al.   JOURNAL OF IMMUNOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses

(2014) Nicole Joller et al.   IMMUNITY

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

(2014) C. Wang et al.   Cancer Immunology Research

Cutting Edge: DNAX Accessory Molecule 1-Deficient CD8+ T Cells Display Immunological Synapse Defects That Impair Antitumor Immunity

(2013) K. M. Ramsbottom et al.   JOURNAL OF IMMUNOLOGY

Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer

(2012) Alexander Pedroza-Gonzalez et al.   HEPATOLOGY

The TIGIT/CD226 Axis Regulates Human T Cell Function

(2012) E. Lozano et al.   JOURNAL OF IMMUNOLOGY

Vstm3 is a member of the CD28 family and an important modulator of T-cell function

(2011) Steven D. Levin et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions

(2011) N. Joller et al.   JOURNAL OF IMMUNOLOGY

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC

(2009) Kent S. Boles et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

(2009) N. Stanietsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diagnosis and Treatment of Hepatocellular Carcinoma

(2008) Hashem B. El-Serag et al.   GASTROENTEROLOGY

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

(2008) Xin Yu et al.   NATURE IMMUNOLOGY